Literature DB >> 17889087

Cortical hyperostosis secondary to prostaglandin E1 therapy.

Kimberly Estes1, Michael Nowicki, Phyllis Bishop.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17889087     DOI： 10.1016/j.jpeds.2007.02.066

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  4 in total

Review 1.  Two Japanese familial cases of Caffey disease with and without the common COL1A1 mutation and normal bone density, and review of the literature.

Authors:  Taichi Kitaoka; Yoko Miyoshi; Noriyuki Namba; Kohji Miura; Takuo Kubota; Yasuhisa Ohata; Makoto Fujiwara; Masaki Takagi; Tomonobu Hasegawa; Harald Jüppner; Keiichi Ozono
Journal:  Eur J Pediatr       Date:  2014-01-04       Impact factor: 3.183

2.  Fetuin-A deficiency is associated with infantile cortical hyperostosis (Caffey disease).

Authors:  Rona Merdler-Rabinowicz; Anna Grinberg; Jeffrey M Jacobson; Ido Somekh; Christoph Klein; Atar Lev; Salama Ihsan; Adib Habib; Raz Somech; Amos J Simon
Journal:  Pediatr Res       Date:  2019-07-09       Impact factor: 3.756

3.  The Osteogenesis Imperfecta Type V Mutant BRIL/IFITM5 Promotes Transcriptional Activation of MEF2, NFATc, and NR4A in Osteoblasts.

Authors:  Vincent Maranda; Marie-Hélène Gaumond; Pierre Moffatt
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

Review 4.  Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions.

Authors:  Smita Akkinapally; Shilpa G Hundalani; Madhulika Kulkarni; Caraciolo J Fernandes; Antonio G Cabrera; Binoy Shivanna; Mohan Pammi
Journal:  Cochrane Database Syst Rev       Date:  2018-02-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.